Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) Stock Competitors & Peer Comparison
See (RLAY) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RLAY | $12.85 | -14.08% | 2.3B | -8.09 | -$1.61 | N/A |
| VRTX | $424.88 | -0.26% | 109.4B | 28.08 | $15.32 | N/A |
| REGN | $686.81 | -7.74% | 76.1B | 17.65 | $41.49 | +0.49% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $768.08 | -2.00% | 48B | 40.01 | $19.37 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $302.60 | -1.92% | 40.3B | 130.22 | $2.32 | N/A |
| RVMD | $141.28 | +7.30% | 30.2B | -24.34 | -$5.95 | N/A |
| INSM | $135.71 | -0.20% | 29.1B | -21.02 | -$6.42 | N/A |
| BNTX | $100.64 | -1.39% | 25.7B | -18.49 | -$5.52 | N/A |
Stock Comparison
RLAY vs VRTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, VRTX has a market cap of 109.4B. Regarding current trading prices, RLAY is priced at $12.85, while VRTX trades at $424.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas VRTX's P/E ratio is 28.08. In terms of profitability, RLAY's ROE is -0.43%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, RLAY is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check VRTX's competition here
RLAY vs REGN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, REGN has a market cap of 76.1B. Regarding current trading prices, RLAY is priced at $12.85, while REGN trades at $686.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas REGN's P/E ratio is 17.65. In terms of profitability, RLAY's ROE is -0.43%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RLAY is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check REGN's competition here
RLAY vs VRNA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RLAY is priced at $12.85, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RLAY's ROE is -0.43%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RLAY is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check VRNA's competition here
RLAY vs ARGX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ARGX has a market cap of 48B. Regarding current trading prices, RLAY is priced at $12.85, while ARGX trades at $768.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ARGX's P/E ratio is 40.01. In terms of profitability, RLAY's ROE is -0.43%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, RLAY is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ARGX's competition here
RLAY vs SGEN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RLAY is priced at $12.85, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RLAY's ROE is -0.43%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RLAY is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check SGEN's competition here
RLAY vs ALNY Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ALNY has a market cap of 40.3B. Regarding current trading prices, RLAY is priced at $12.85, while ALNY trades at $302.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ALNY's P/E ratio is 130.22. In terms of profitability, RLAY's ROE is -0.43%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, RLAY is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ALNY's competition here
RLAY vs RVMD Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RVMD has a market cap of 30.2B. Regarding current trading prices, RLAY is priced at $12.85, while RVMD trades at $141.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RVMD's P/E ratio is -24.34. In terms of profitability, RLAY's ROE is -0.43%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, RLAY is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RVMD's competition here
RLAY vs INSM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, INSM has a market cap of 29.1B. Regarding current trading prices, RLAY is priced at $12.85, while INSM trades at $135.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas INSM's P/E ratio is -21.02. In terms of profitability, RLAY's ROE is -0.43%, compared to INSM's ROE of -1.68%. Regarding short-term risk, RLAY is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check INSM's competition here
RLAY vs BNTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BNTX has a market cap of 25.7B. Regarding current trading prices, RLAY is priced at $12.85, while BNTX trades at $100.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BNTX's P/E ratio is -18.49. In terms of profitability, RLAY's ROE is -0.43%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, RLAY is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BNTX's competition here
RLAY vs UTHR Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, UTHR has a market cap of 24.9B. Regarding current trading prices, RLAY is priced at $12.85, while UTHR trades at $573.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas UTHR's P/E ratio is 20.43. In terms of profitability, RLAY's ROE is -0.43%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RLAY is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check UTHR's competition here
RLAY vs RPRX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RPRX has a market cap of 21.2B. Regarding current trading prices, RLAY is priced at $12.85, while RPRX trades at $49.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RPRX's P/E ratio is 27.83. In terms of profitability, RLAY's ROE is -0.43%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, RLAY is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RPRX's competition here
RLAY vs BGNE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RLAY is priced at $12.85, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RLAY's ROE is -0.43%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, RLAY is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BGNE's competition here
RLAY vs ROIV Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, RLAY is priced at $12.85, while ROIV trades at $27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ROIV's P/E ratio is -23.74. In terms of profitability, RLAY's ROE is -0.43%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, RLAY is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ROIV's competition here
RLAY vs INCY Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, RLAY is priced at $12.85, while INCY trades at $98.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas INCY's P/E ratio is 15.26. In terms of profitability, RLAY's ROE is -0.43%, compared to INCY's ROE of +0.41%. Regarding short-term risk, RLAY is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check INCY's competition here
RLAY vs DNA-WT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RLAY is priced at $12.85, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RLAY's ROE is -0.43%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, RLAY is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check DNA-WT's competition here
RLAY vs MRNA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MRNA has a market cap of 18.7B. Regarding current trading prices, RLAY is priced at $12.85, while MRNA trades at $45.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MRNA's P/E ratio is -6.49. In terms of profitability, RLAY's ROE is -0.43%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RLAY is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check MRNA's competition here
RLAY vs GMAB Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, RLAY is priced at $12.85, while GMAB trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas GMAB's P/E ratio is 17.40. In terms of profitability, RLAY's ROE is -0.43%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, RLAY is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check GMAB's competition here
RLAY vs SMMT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, SMMT has a market cap of 16.5B. Regarding current trading prices, RLAY is priced at $12.85, while SMMT trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas SMMT's P/E ratio is -14.76. In terms of profitability, RLAY's ROE is -0.43%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, RLAY is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check SMMT's competition here
RLAY vs ASND Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ASND has a market cap of 13.6B. Regarding current trading prices, RLAY is priced at $12.85, while ASND trades at $217.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ASND's P/E ratio is -49.44. In terms of profitability, RLAY's ROE is -0.43%, compared to ASND's ROE of +1.28%. Regarding short-term risk, RLAY is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ASND's competition here
RLAY vs BBIO Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, RLAY is priced at $12.85, while BBIO trades at $70.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BBIO's P/E ratio is -18.43. In terms of profitability, RLAY's ROE is -0.43%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, RLAY is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BBIO's competition here
RLAY vs KRTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RLAY is priced at $12.85, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RLAY's ROE is -0.43%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RLAY is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check KRTX's competition here
RLAY vs JAZZ Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, JAZZ has a market cap of 12.6B. Regarding current trading prices, RLAY is priced at $12.85, while JAZZ trades at $201.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas JAZZ's P/E ratio is -34.93. In terms of profitability, RLAY's ROE is -0.43%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, RLAY is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check JAZZ's competition here
RLAY vs IONS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, IONS has a market cap of 11.9B. Regarding current trading prices, RLAY is priced at $12.85, while IONS trades at $73.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas IONS's P/E ratio is -30.16. In terms of profitability, RLAY's ROE is -0.43%, compared to IONS's ROE of -0.69%. Regarding short-term risk, RLAY is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check IONS's competition here
RLAY vs MDGL Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, RLAY is priced at $12.85, while MDGL trades at $515.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MDGL's P/E ratio is -40.18. In terms of profitability, RLAY's ROE is -0.43%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, RLAY is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MDGL's competition here
RLAY vs EXEL Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, RLAY is priced at $12.85, while EXEL trades at $44.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas EXEL's P/E ratio is 16.16. In terms of profitability, RLAY's ROE is -0.43%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, RLAY is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check EXEL's competition here
RLAY vs RNAM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RLAY is priced at $12.85, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RLAY's ROE is -0.43%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RLAY is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RNAM's competition here
RLAY vs BMRN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BMRN has a market cap of 10.3B. Regarding current trading prices, RLAY is priced at $12.85, while BMRN trades at $54.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BMRN's P/E ratio is 29.61. In terms of profitability, RLAY's ROE is -0.43%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, RLAY is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BMRN's competition here
RLAY vs ARWR Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ARWR has a market cap of 9.8B. Regarding current trading prices, RLAY is priced at $12.85, while ARWR trades at $69.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ARWR's P/E ratio is 43.84. In terms of profitability, RLAY's ROE is -0.43%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, RLAY is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ARWR's competition here
RLAY vs RXDX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RLAY is priced at $12.85, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RLAY's ROE is -0.43%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RLAY is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RXDX's competition here
RLAY vs AXSM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, AXSM has a market cap of 9.5B. Regarding current trading prices, RLAY is priced at $12.85, while AXSM trades at $184.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas AXSM's P/E ratio is -50.27. In terms of profitability, RLAY's ROE is -0.43%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, RLAY is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check AXSM's competition here
RLAY vs IMGN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RLAY is priced at $12.85, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RLAY's ROE is -0.43%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RLAY is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check IMGN's competition here
RLAY vs PCVX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, RLAY is priced at $12.85, while PCVX trades at $57.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas PCVX's P/E ratio is -10.43. In terms of profitability, RLAY's ROE is -0.43%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, RLAY is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check PCVX's competition here
RLAY vs TECH Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, RLAY is priced at $12.85, while TECH trades at $51.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas TECH's P/E ratio is 100.96. In terms of profitability, RLAY's ROE is -0.43%, compared to TECH's ROE of +0.04%. Regarding short-term risk, RLAY is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check TECH's competition here
RLAY vs BPMC Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RLAY is priced at $12.85, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RLAY's ROE is -0.43%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RLAY is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BPMC's competition here
RLAY vs CERE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RLAY is priced at $12.85, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CERE's P/E ratio is -16.47. In terms of profitability, RLAY's ROE is -0.43%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RLAY is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CERE's competition here
RLAY vs KRYS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, RLAY is priced at $12.85, while KRYS trades at $262.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas KRYS's P/E ratio is 39.31. In terms of profitability, RLAY's ROE is -0.43%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RLAY is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check KRYS's competition here
RLAY vs HALO Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, RLAY is priced at $12.85, while HALO trades at $63.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas HALO's P/E ratio is 24.95. In terms of profitability, RLAY's ROE is -0.43%, compared to HALO's ROE of +0.93%. Regarding short-term risk, RLAY is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check HALO's competition here
RLAY vs CYTK Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, RLAY is priced at $12.85, while CYTK trades at $60.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CYTK's P/E ratio is -9.28. In terms of profitability, RLAY's ROE is -0.43%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, RLAY is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CYTK's competition here
RLAY vs NUVL Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, RLAY is priced at $12.85, while NUVL trades at $99.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas NUVL's P/E ratio is -17.43. In terms of profitability, RLAY's ROE is -0.43%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, RLAY is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check NUVL's competition here
RLAY vs MTSR Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RLAY is priced at $12.85, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RLAY's ROE is -0.43%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RLAY is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MTSR's competition here
RLAY vs ABVX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, RLAY is priced at $12.85, while ABVX trades at $107.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ABVX's P/E ratio is -19.41. In terms of profitability, RLAY's ROE is -0.43%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, RLAY is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ABVX's competition here
RLAY vs IBRX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, IBRX has a market cap of 7.2B. Regarding current trading prices, RLAY is priced at $12.85, while IBRX trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas IBRX's P/E ratio is -18.32. In terms of profitability, RLAY's ROE is -0.43%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, RLAY is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check IBRX's competition here
RLAY vs KYMR Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, KYMR has a market cap of 6.8B. Regarding current trading prices, RLAY is priced at $12.85, while KYMR trades at $81.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas KYMR's P/E ratio is -22.72. In terms of profitability, RLAY's ROE is -0.43%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, RLAY is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check KYMR's competition here
RLAY vs MRUS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RLAY is priced at $12.85, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RLAY's ROE is -0.43%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RLAY is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MRUS's competition here
RLAY vs PRAX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, RLAY is priced at $12.85, while PRAX trades at $321.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas PRAX's P/E ratio is -23.88. In terms of profitability, RLAY's ROE is -0.43%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, RLAY is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check PRAX's competition here
RLAY vs ACLX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RLAY is priced at $12.85, while ACLX trades at $115.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RLAY's ROE is -0.43%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RLAY is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ACLX's competition here
RLAY vs RETA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RLAY is priced at $12.85, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RETA's P/E ratio is -66.29. In terms of profitability, RLAY's ROE is -0.43%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RLAY is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RETA's competition here
RLAY vs PTGX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, RLAY is priced at $12.85, while PTGX trades at $99.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas PTGX's P/E ratio is -49.37. In terms of profitability, RLAY's ROE is -0.43%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, RLAY is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check PTGX's competition here
RLAY vs BLTE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, RLAY is priced at $12.85, while BLTE trades at $156.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BLTE's P/E ratio is -70.23. In terms of profitability, RLAY's ROE is -0.43%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, RLAY is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BLTE's competition here
RLAY vs COGT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, RLAY is priced at $12.85, while COGT trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas COGT's P/E ratio is -16.82. In terms of profitability, RLAY's ROE is -0.43%, compared to COGT's ROE of -1.00%. Regarding short-term risk, RLAY is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check COGT's competition here
RLAY vs CNTA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, RLAY is priced at $12.85, while CNTA trades at $39.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CNTA's P/E ratio is -27.03. In terms of profitability, RLAY's ROE is -0.43%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, RLAY is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CNTA's competition here
RLAY vs PTCT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, RLAY is priced at $12.85, while PTCT trades at $64.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas PTCT's P/E ratio is 8.19. In terms of profitability, RLAY's ROE is -0.43%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, RLAY is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check PTCT's competition here
RLAY vs CELC Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CELC has a market cap of 5.8B. Regarding current trading prices, RLAY is priced at $12.85, while CELC trades at $118.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CELC's P/E ratio is -31.68. In terms of profitability, RLAY's ROE is -0.43%, compared to CELC's ROE of -2.03%. Regarding short-term risk, RLAY is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CELC's competition here
RLAY vs RYTM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, RLAY is priced at $12.85, while RYTM trades at $81.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RYTM's P/E ratio is -27.07. In terms of profitability, RLAY's ROE is -0.43%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, RLAY is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RYTM's competition here
RLAY vs ALKS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ALKS has a market cap of 5.7B. Regarding current trading prices, RLAY is priced at $12.85, while ALKS trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ALKS's P/E ratio is 23.87. In terms of profitability, RLAY's ROE is -0.43%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, RLAY is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ALKS's competition here
RLAY vs CDTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RLAY is priced at $12.85, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RLAY's ROE is -0.43%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RLAY is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CDTX's competition here
RLAY vs CGON Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, RLAY is priced at $12.85, while CGON trades at $65.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CGON's P/E ratio is -31.51. In terms of profitability, RLAY's ROE is -0.43%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RLAY is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CGON's competition here
RLAY vs ABCM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RLAY is priced at $12.85, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RLAY's ROE is -0.43%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RLAY is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ABCM's competition here
RLAY vs TGTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, RLAY is priced at $12.85, while TGTX trades at $33.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas TGTX's P/E ratio is 12.48. In terms of profitability, RLAY's ROE is -0.43%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, RLAY is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check TGTX's competition here
RLAY vs ISEE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RLAY is priced at $12.85, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RLAY's ROE is -0.43%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RLAY is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ISEE's competition here
RLAY vs IMVT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, RLAY is priced at $12.85, while IMVT trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas IMVT's P/E ratio is -10.11. In terms of profitability, RLAY's ROE is -0.43%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, RLAY is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check IMVT's competition here
RLAY vs SRRK Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, RLAY is priced at $12.85, while SRRK trades at $46.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas SRRK's P/E ratio is -14.20. In terms of profitability, RLAY's ROE is -0.43%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, RLAY is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check SRRK's competition here
RLAY vs APLS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, RLAY is priced at $12.85, while APLS trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas APLS's P/E ratio is 227.72. In terms of profitability, RLAY's ROE is -0.43%, compared to APLS's ROE of +0.08%. Regarding short-term risk, RLAY is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check APLS's competition here
RLAY vs CAI Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, RLAY is priced at $12.85, while CAI trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CAI's P/E ratio is -5.73. In terms of profitability, RLAY's ROE is -0.43%, compared to CAI's ROE of +0.25%. Regarding short-term risk, RLAY is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CAI's competition here
RLAY vs FBIOX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, RLAY is priced at $12.85, while FBIOX trades at $24.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RLAY's ROE is -0.43%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RLAY is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check FBIOX's competition here
RLAY vs CRSP Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, RLAY is priced at $12.85, while CRSP trades at $51.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CRSP's P/E ratio is -8.05. In terms of profitability, RLAY's ROE is -0.43%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, RLAY is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CRSP's competition here
RLAY vs CORT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CORT has a market cap of 5B. Regarding current trading prices, RLAY is priced at $12.85, while CORT trades at $47.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CORT's P/E ratio is 56.85. In terms of profitability, RLAY's ROE is -0.43%, compared to CORT's ROE of +0.15%. Regarding short-term risk, RLAY is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CORT's competition here
RLAY vs APGE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, RLAY is priced at $12.85, while APGE trades at $82.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas APGE's P/E ratio is -20.23. In terms of profitability, RLAY's ROE is -0.43%, compared to APGE's ROE of -0.37%. Regarding short-term risk, RLAY is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check APGE's competition here
RLAY vs TERN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RLAY is priced at $12.85, while TERN trades at $52.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas TERN's P/E ratio is -51.40. In terms of profitability, RLAY's ROE is -0.43%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RLAY is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check TERN's competition here
RLAY vs MIRM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, RLAY is priced at $12.85, while MIRM trades at $94.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MIRM's P/E ratio is -200.00. In terms of profitability, RLAY's ROE is -0.43%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, RLAY is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MIRM's competition here
RLAY vs LGND Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, RLAY is priced at $12.85, while LGND trades at $227.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas LGND's P/E ratio is 37.90. In terms of profitability, RLAY's ROE is -0.43%, compared to LGND's ROE of +0.14%. Regarding short-term risk, RLAY is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check LGND's competition here
RLAY vs FOLD Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RLAY is priced at $12.85, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RLAY's ROE is -0.43%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RLAY is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check FOLD's competition here
RLAY vs AKRO Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RLAY is priced at $12.85, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RLAY's ROE is -0.43%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RLAY is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check AKRO's competition here
RLAY vs ALPN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RLAY is priced at $12.85, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RLAY's ROE is -0.43%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RLAY is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ALPN's competition here
RLAY vs LEGN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, LEGN has a market cap of 4.4B. Regarding current trading prices, RLAY is priced at $12.85, while LEGN trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas LEGN's P/E ratio is -14.54. In terms of profitability, RLAY's ROE is -0.43%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, RLAY is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check LEGN's competition here
RLAY vs XENE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, RLAY is priced at $12.85, while XENE trades at $56.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas XENE's P/E ratio is -12.51. In terms of profitability, RLAY's ROE is -0.43%, compared to XENE's ROE of -0.56%. Regarding short-term risk, RLAY is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check XENE's competition here
RLAY vs OPT Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RLAY is priced at $12.85, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas OPT's P/E ratio is -1.52. In terms of profitability, RLAY's ROE is -0.43%, compared to OPT's ROE of +0.88%. Regarding short-term risk, RLAY is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check OPT's competition here
RLAY vs SYRE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, SYRE has a market cap of 4.1B. Regarding current trading prices, RLAY is priced at $12.85, while SYRE trades at $73.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas SYRE's P/E ratio is -34.66. In terms of profitability, RLAY's ROE is -0.43%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, RLAY is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check SYRE's competition here
RLAY vs MRTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RLAY is priced at $12.85, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RLAY's ROE is -0.43%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RLAY is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MRTX's competition here
RLAY vs KNSA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, KNSA has a market cap of 4B. Regarding current trading prices, RLAY is priced at $12.85, while KNSA trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas KNSA's P/E ratio is 71.80. In terms of profitability, RLAY's ROE is -0.43%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RLAY is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check KNSA's competition here
RLAY vs CRNX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, RLAY is priced at $12.85, while CRNX trades at $37.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CRNX's P/E ratio is -7.71. In terms of profitability, RLAY's ROE is -0.43%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, RLAY is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CRNX's competition here
RLAY vs MANE Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, MANE has a market cap of 3.9B. Regarding current trading prices, RLAY is priced at $12.85, while MANE trades at $104.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas MANE's P/E ratio is -43.73. In terms of profitability, RLAY's ROE is -0.43%, compared to MANE's ROE of -0.76%. Regarding short-term risk, RLAY is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check MANE's competition here
RLAY vs ACAD Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, RLAY is priced at $12.85, while ACAD trades at $22.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ACAD's P/E ratio is 9.86. In terms of profitability, RLAY's ROE is -0.43%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, RLAY is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ACAD's competition here
RLAY vs TVTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, TVTX has a market cap of 3.8B. Regarding current trading prices, RLAY is priced at $12.85, while TVTX trades at $40.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas TVTX's P/E ratio is -71.74. In terms of profitability, RLAY's ROE is -0.43%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, RLAY is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check TVTX's competition here
RLAY vs VKTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, RLAY is priced at $12.85, while VKTX trades at $31.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas VKTX's P/E ratio is -10.15. In terms of profitability, RLAY's ROE is -0.43%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, RLAY is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check VKTX's competition here
RLAY vs RYZB Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RLAY is priced at $12.85, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RLAY's ROE is -0.43%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RLAY is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check RYZB's competition here
RLAY vs CBAY Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RLAY is priced at $12.85, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RLAY's ROE is -0.43%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RLAY is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CBAY's competition here
RLAY vs CPRX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, CPRX has a market cap of 3.6B. Regarding current trading prices, RLAY is priced at $12.85, while CPRX trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas CPRX's P/E ratio is 17.52. In terms of profitability, RLAY's ROE is -0.43%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RLAY is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check CPRX's competition here
RLAY vs SWTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RLAY is priced at $12.85, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RLAY's ROE is -0.43%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RLAY is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check SWTX's competition here
RLAY vs TLX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, RLAY is priced at $12.85, while TLX trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas TLX's P/E ratio is -522.00. In terms of profitability, RLAY's ROE is -0.43%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RLAY is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check TLX's competition here
RLAY vs EWTX Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, EWTX has a market cap of 3.3B. Regarding current trading prices, RLAY is priced at $12.85, while EWTX trades at $30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas EWTX's P/E ratio is -19.01. In terms of profitability, RLAY's ROE is -0.43%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, RLAY is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check EWTX's competition here
RLAY vs LQDA Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, RLAY is priced at $12.85, while LQDA trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas LQDA's P/E ratio is -47.06. In terms of profitability, RLAY's ROE is -0.43%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, RLAY is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check LQDA's competition here
RLAY vs NAMS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, RLAY is priced at $12.85, while NAMS trades at $28.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas NAMS's P/E ratio is -17.62. In terms of profitability, RLAY's ROE is -0.43%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, RLAY is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check NAMS's competition here
RLAY vs DNTH Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, RLAY is priced at $12.85, while DNTH trades at $83.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas DNTH's P/E ratio is -19.92. In terms of profitability, RLAY's ROE is -0.43%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, RLAY is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check DNTH's competition here
RLAY vs DNLI Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, RLAY is priced at $12.85, while DNLI trades at $18.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas DNLI's P/E ratio is -6.75. In terms of profitability, RLAY's ROE is -0.43%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, RLAY is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check DNLI's competition here
RLAY vs BEAM Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, RLAY is priced at $12.85, while BEAM trades at $29.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas BEAM's P/E ratio is -37.73. In terms of profitability, RLAY's ROE is -0.43%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, RLAY is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check BEAM's competition here
RLAY vs ERAS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ERAS has a market cap of 3.1B. Regarding current trading prices, RLAY is priced at $12.85, while ERAS trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ERAS's P/E ratio is -22.50. In terms of profitability, RLAY's ROE is -0.43%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, RLAY is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RLAY.Check ERAS's competition here
RLAY vs DYN Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, RLAY is priced at $12.85, while DYN trades at $17.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas DYN's P/E ratio is -5.23. In terms of profitability, RLAY's ROE is -0.43%, compared to DYN's ROE of -0.61%. Regarding short-term risk, RLAY is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check DYN's competition here
RLAY vs ALMS Comparison April 2026
RLAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RLAY stands at 2.3B. In comparison, ALMS has a market cap of 3B. Regarding current trading prices, RLAY is priced at $12.85, while ALMS trades at $23.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RLAY currently has a P/E ratio of -8.09, whereas ALMS's P/E ratio is -8.40. In terms of profitability, RLAY's ROE is -0.43%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, RLAY is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for RLAY.Check ALMS's competition here